+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn

+ Translate
+ Recently Requested

Treatment of Epstein-Barr virus-associated malignancies with specific T cells



Treatment of Epstein-Barr virus-associated malignancies with specific T cells



Advances in Cancer Research 84: 175-201



Latent Epstein-Barr virus (EBV) infection is associated with a heterogeneous group of malignancies, including Burkitt's lymphoma, Hodgkin's disease, nasopharyngeal carcinoma, and lymphoproliferative disease (LPD). The development of adoptive immunotherapies for these malignancies is being fueled by the successful generation of allogeneic donor derived EBV-specific cytotoxic T cells (CTL) for the prevention and treatment of EBV-LPD after hematopoietic stem cell transplantation. This approach is being extended to EBV-LPD after solid organ transplantation by use of autologous and haploidentical EBV-specific CTL. For other EBV-associated malignancies, there is only limited clinical experience with EBV-specific CTL. With few exceptions, only patients with recurrent Hodgkin's disease have been treated with autologous EBV-specific CTL, and although the results have been promising, they do not include cures. Lack of CTL efficacy may reflect either down-regulation of immunodominant EBV proteins, which are major CTL targets, or the presence of inhibitory cytokines. Further improvement of EBV-specific CTL therapy for Hodgkin's disease will require improved methods to activate and expand CTL specific for the latent EBV genes expressed in Hodgkin's disease and to genetically modify the expanded CTL to render them resistant to inhibitory cytokines. If effective, such strategies could be applied not only to other EBV-associated malignancies, but also to a broad range of human tumors with defined tumor antigens and similar immune evasion strategies.

(PDF emailed within 1 workday: $29.90)

Accession: 035980401

Download citation: RISBibTeXText

PMID: 11883527


Related references

Epstein-Barr virus-specific cytokine-induced killer cells for treatment of Epstein-Barr virus-related malignant lymphoma. CytoTherapy 20(6): 839-850, 2018

Epstein-Barr virus nuclear antigen 1-specific CD4+ T cells directly kill Epstein-Barr virus-carrying natural killer and T cells. Cancer Science 99(8): 1633-1642, 2008

Establishment of epstein barr virus nuclear antigen expressing cell lines by infection of epstein barr virus genome negative human lymphoma cells with different epstein barr virus strains. International Journal Of Cancer: 161-166, 1976

Relationship between the amounts of epstein barr virus dna and epstein barr virus nuclear antigen per cell clonability and tumorigenicity in 2 epstein barr virus negative lymphoma lines and their epstein barr virus converted sublines. International Journal of Cancer 31(2): 163-170, 1983

Induction of the Epstein-Barr virus thymidine kinase gene with concomitant nucleoside antivirals as a therapeutic strategy for Epstein-Barr virus-associated malignancies. Current Opinion in Oncology 13(5): 360-367, 2001

Generation in vitro of hla restricted epstein barr virus specific cyto toxic human t cells by autologous lympho blastoid cell lines the roles of previous epstein barr virus infection and fetal calf serum. International Journal of Cancer 29(1): 41-48, 1982

Genome-wide profiling of Epstein-Barr virus integration by targeted sequencing in Epstein-Barr virus associated malignancies. Theranostics 9(4): 1115-1124, 2019

Specific allergen-induced Epstein-Barr nuclear antigen-positive B cells from patients with chronic-active Epstein-Barr virus infections. Journal of Allergy and Clinical Immunology 78(2): 315-320, 1986

Comparison of short term and continuous treatment of epstein barr virus nonproducer cells with tumor promoting agent in inducing epstein barr virus early antigen. Abstracts of the Annual Meeting of the American Society for Microbiology 82: ABSTRACT S24, 1982

Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity: implications for immunotherapy of Epstein-Barr virus-associated malignancies. European Journal of Immunology 29(8): 2579-2589, 1999

Combination of Epstein-Barr virus nuclear antigen 1, 3 and lytic antigen BZLF1 peptide pools allows fast and efficient stimulation of Epstein-Barr virus-specific T cells for adoptive immunotherapy. CytoTherapy 16(1): 122-134, 2014

Epstein-Barr virus-specific T cells for the management of Epstein-Barr virus lymphomas. Current Opinion in Oncology 13(5): 349-353, 2001

A comparison of Epstein-Barr virus specific proteins expressed by three Epstein-Barr virus isolates using specific monoclonal antibodies. Intervirology 32(6): 376-382, 1991

Epstein barr virus induced proteins 5. comparison of epstein barr virus specific poly peptides from different virus strains. Medical Microbiology and Immunology 171(1): 11-22, 1982

Positivity of both plasma Epstein-Barr virus DNA and serum Epstein-Barr virus capsid specific immunoglobulin A is a better prognostic biomarker for nasopharyngeal carcinoma. Bba Clinical 2: 88-93, 2015